CLDX FY 2025 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-78.6% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$287M-19160.0% margin

Net Income

-$259M-17253.3% margin

EPS (Diluted)

$-3.90

Cash Flow

Operating Cash Flow

-$211M

Free Cash Flow

-$214M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$583M

Total Liabilities

$56M

Stockholders' Equity

$527M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$7M	-78.6%
Gross Profit	$2M	-$157M	+101.0%
Operating Income	-$287M	-$195M	-47.3%
Net Income	-$259M	-$158M	-63.9%